Patient A and Patient B enter the oncology department. Both have a cancer that originated in the bile ducts, and both have been diagnosed with cholangiocarcinoma. At first glance, it may seem obvious that they should receive the same treatment.
But is that really how cancer treatment works?
The answer is not always yes. Even when two patients have the same cancer diagnosis, their tumors can have different molecular characteristics, their disease may be at a different stage, and their previous treatment history may not be the same. These differences can influence which treatment options are considered appropriate.
Let’s look at the two patients more closely.
Same Diagnosis: Cholangiocarcinoma
Here is where the story begins. Both Patient A and Patient B have cholangiocarcinoma, a cancer that develops in the bile ducts.
Diagnosing and staging cholangiocarcinoma can involve several tests and procedures. Depending on the individual case, doctors may use blood tests, liver function tests, imaging such as CT or MRI, magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP), biopsy and other investigations to understand the location and extent of the cancer. Molecular or biomarker testing may also be performed to identify genetic changes that could influence treatment selection. Not every patient will need every test.
So although both patients have the same diagnosis, the next question is: What does their tumor profile show?
Patient A
Patient A has previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. Molecular testing identifies an FGFR2 fusion or other rearrangement.
This finding can make Patient A a candidate for Pemigatinib, because Pemigatinib is approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma whose tumor has an FGFR2 fusion or other rearrangement detected by an FDA-approved test.
Pemigatinib is a targeted therapy belonging to a group of medicines called fibroblast growth factor receptor (FGFR) inhibitors. It works by blocking signaling through FGFR proteins, including FGFR2, that can contribute to cancer-cell growth and survival.
Therefore, the presence of the relevant FGFR2 alteration is an important factor when considering Pemigatinib for this particular cholangiocarcinoma setting.
Patient B
Now consider Patient B.
Patient B also has cholangiocarcinoma, but molecular testing does not identify an FGFR2 fusion or other rearrangement that would meet the selection criteria for Pemigatinib in this indication.
The diagnosis is the same, but the molecular profile is different.
As a result, Pemigatinib would not simply be selected because Patient B has cholangiocarcinoma. The oncology team would consider other appropriate treatment options based on factors such as the extent of disease, previous treatment, molecular findings, overall health and other clinical considerations.
This is an important part of modern cancer treatment: the name of the cancer is only one part of the treatment decision.
Why Does Molecular Testing Matter?
Cancer cells can carry genetic changes that are different from those found in another person’s cancer, even when both cancers are classified under the same disease name.
In cholangiocarcinoma, FGFR2 fusions and rearrangements are examples of molecular alterations that can help identify patients who may be suitable for an FGFR-targeted treatment. NCI notes that FGFR2 gene fusions occur in a subset of intrahepatic cholangiocarcinomas and can be relevant when considering FGFR inhibitors.
This is why biomarker testing can be an important part of treatment planning. It provides information about the biological characteristics of the tumor rather than relying only on its location or diagnosis.
For a patient considering Pemigatinib, the presence of the appropriate FGFR2 fusion or rearrangement is particularly important.
Deciding Factors for Appropriate Treatment Options
Biomarker results are important, but they are not the only information doctors consider when developing a treatment plan.
Other factors may include:
- Previous treatment history: The medicines or therapies already received and how the cancer responded to them can influence what is considered next.
- Disease extent: Whether the cancer is localized, locally advanced, unresectable or metastatic can affect the treatment approach.
- Molecular profile: Genetic and molecular findings may identify targeted treatment options or help rule out treatments that are not appropriate for a particular tumor.
- Overall health: A patient’s general condition and ability to tolerate a particular treatment are important considerations.
- Organ function: Liver and kidney function may influence the selection or dosing of certain medicines.
- Other medicines: Existing medications can be relevant because of possible drug interactions or overlapping effects.
- Potential treatment risks: The healthcare team considers the expected benefits alongside the possible adverse effects and other risks of treatment.
Therefore, treatment selection is not simply a matter of matching a medicine to a cancer name. It involves bringing together information from diagnosis, molecular testing, previous treatment and the patient’s current clinical condition.
Questions Patients May Ask Before Pemigatinib Therapy
Patients may have several questions before starting a targeted treatment. Discussing these questions with the treating oncologist can help make the treatment decision clearer.
- Has my tumor been tested for relevant FGFR2 alterations?
- Does my test result meet the criteria for Pemigatinib treatment?
- What other treatment options may be appropriate for my condition?
- How does my previous treatment history affect the next treatment decision?
- What potential adverse effects should I discuss with my healthcare team before starting treatment?
- Are there any medicines or health conditions that could affect my treatment plan?
These questions do not replace medical advice, but they can help patients have a more informed discussion with their oncology team.
The Same Cancer Does Not Always Mean the Same Treatment
Patient A and Patient B started with the same diagnosis: cholangiocarcinoma.
But their treatment pathways may differ because their tumors do not necessarily have the same molecular characteristics or clinical history.
For Patient A, an appropriate FGFR2 fusion or rearrangement in the setting of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma may make Pemigatinib a relevant treatment option. For Patient B, the absence of the required FGFR2 alteration means that the same medicine would not automatically be appropriate for the same indication.
This is the basis of more individualized cancer care. Treatment decisions are made by looking beyond the cancer’s name and considering the characteristics of the tumor and the person receiving treatment.
If you are looking to buy Pemigatinib in India or need guidance regarding its availability and procurement, contact us at +91 9967979080 can provide information about the applicable access and medicine import process. Assistance is available for requests to buy Pemigatinib in Mumbai , Delhi, Chennai, Kolkata and other locations across India. The appropriate treatment, however, should always be determined by the treating oncologist based on the patient’s diagnosis, molecular test results and overall clinical condition.
The right treatment is not selected randomly. It is chosen after considering the information available about the cancer and the individual patient. Understanding why two people with the same diagnosis may receive different treatments can help patients approach these treatment decisions with greater clarity.
